George Magrath, Chief Executive Officer and Director of Opus Genetics, Inc., filed a statement of changes in beneficial ownership on October 27, 2026, reporting an automatic sale of common stock on October 23, 2026, to satisfy tax withholding obligations tied to the vesting and settlement of restricted stock units.

Key Highlights

  • Reporting person: George Magrath, Chief Executive Officer and Director of Opus Genetics, Inc.
  • Transaction date: October 23, 2026, with the filing submitted on October 27, 2026.
  • Shares disposed: 9,591 shares of common stock sold at $3.585 per share, transaction code S.
  • Automatic sale: According to the filing, the shares "were sold automatically on behalf of the Reporting Person, as required by the Issuer to satisfy tax withholding obligations that arose in connection with the vesting and settlement of restricted stock units."
  • Resulting ownership: Following the transaction, Magrath directly holds 2,038,894 shares of common stock.
  • Non-discretionary trade: The filing states "this transaction does not represent a discretionary trade by the Reporting Person."

George Magrath's RSU Tax Withholding Sale at Opus Genetics

According to the filing, George Magrath, who serves as both Chief Executive Officer and a Director of Opus Genetics, Inc. (NASDAQ:IRD), disposed of 9,591 shares of common stock on October 23, 2026. The sale price was $3.585 per share, and the transaction was coded "S" in the filing's Table I, covering non-derivative securities acquired, disposed of, or beneficially owned.

The filing's explanation of responses makes clear that this sale was not initiated at Magrath's discretion. The shares were sold automatically as required by the issuer to cover tax withholding obligations that arose when restricted stock units vested and settled. Opus Genetics is a biotechnology company focused on genetic medicine, operating in the ophthalmology segment. Following the reported transaction, Magrath's direct beneficial ownership of Opus Genetics common stock stands at 2,038,894 shares, according to the filing. No derivative securities transactions were reported in Table II.

The filing was signed by Amy Rabourn, acting under power of attorney, and was submitted to the Securities and Exchange Commission on October 27, 2026. The filing indicates this was made by one reporting person and was not an amendment to a prior filing.

What Was Disclosed

Opus Genetics CEO George Magrath reported an automatic disposition of 9,591 shares of common stock at $3.585 per share on October 23, 2026, to meet tax withholding requirements from restricted stock unit vesting, leaving him with direct beneficial ownership of 2,038,894 shares.